Perfuze CEO Lays Out the Challenge – and the Promise – of Buildin...
The latest Device Talks weekly podcast recapped the successful Minnesota gathering and turned its focus to the upcoming Device Talks Boston conference, slated for May 27‑28. Organizers highlighted a 25% early‑bird discount (code DTW25) and a packed agenda featuring keynotes, panels on Massachusetts medtech, and an expo floor designed to foster industry connections. Beyond event promotion, the episode surveyed pivotal MedTech developments. Danaher’s $10 billion acquisition of Massimo was confirmed, signaling aggressive consolidation in digital health. ResMed announced a $340 million purchase of Nocttrix Health, extending its portfolio into wearable therapies for restless‑leg syndrome and broader sleep‑health solutions. Meanwhile, J&J reported that its Atava surgical robot met primary endpoints in a bariatric study, positioning the conglomerate for a deeper entry into the surgical robotics arena. Hosts quoted executives and analysts to underscore the strategic relevance of these moves. Danaher’s CEO emphasized the “extra mojo” the deal brings to its diagnostics platform, while ResMed’s leadership framed the Nocttrix acquisition as a step toward becoming a comprehensive sleep‑health company. J&J’s trial success was described as a “beach‑head” for future robotic applications across specialties. The combined narrative illustrates a medtech sector in flux: large incumbents are bolstering capabilities through high‑value M&A, while niche innovators seek scale via strategic partnerships. Industry events like Device Talks serve as crucial venues for networking, knowledge exchange, and the acceleration of these transformative trends.
Patients Are the Co-Designer — Plexāā’s Gaele Lalahy
The Women in MedTech podcast episode features Gail Lalahy, COO of Plexa, discussing the company's 'patient as co‑designer' philosophy behind its Bloom device and how that approach reshapes product development. Plexa has institutionalized a rule that no decision proceeds without patient...
OrthAlign CEO Eric Timko on the Opportunity for Fast Followers In...
The Device Talks podcast episode provides a broad snapshot of the current med‑tech landscape, from regulatory shifts and financing to cybersecurity and market growth. Host Tom Le and guests discuss recent events such as the MedTech Innovator Radar Forum, FDA...
New Pharaoh CEO Amaza Reitmeier Explains Why Now’s the Time to Ta...
The Device Talks episode centers on Amaza Reitmeier, the newly appointed CEO of Pharaoh Neuro, who explains why the company believes the current moment is optimal for advancing its neuro‑technology platform. Reitmeier, a former Medtronic executive, details her decision to...
Can Abbott’s Connected Neuromodulation Platforms Improve Life For...
The latest Abbott Talks podcast episode spotlights Abbott’s connected neuromodulation platform, a suite of implantable devices that communicate wirelessly with clinicians, electronic health records and AI‑driven decision tools. Host Tom Salmi and guests, including R&D vice‑president Rebecca Wilkins, discuss how...
CEO Stephen From Is Building Tested Strategies Into a New Plan To...
The episode centers on Stephen, the newly appointed CEO of Vicarius Surgical, who argues that the company should be viewed primarily as a medical‑device firm rather than a pure robotics play. He outlines a “tested strategies” framework that prioritizes regulatory...
How Generative AI Can Make Diabetes Care Proactive, Not Reactive
Dexcom CTO Girish Naganathan highlights that behavior change remains the toughest hurdle in diabetes care. By pairing continuous glucose monitoring (CGM) with generative AI, raw glucose data can be transformed into real‑time, actionable recommendations. The technology aims to shift guidance...
Armor Medical’s Wearable Could Give Earlier Warnings of Severe He...
The episode centers on Armor Medical’s breakthrough wearable, which earned the company the grand prize at the MedTech Innovator competition. Host Tom Salmi interviews CEO Kelsey Mayo, highlighting how the sensor could alert patients and clinicians to impending severe health...
Neurotechnology’s Role Beyond Drugs in Treating Brain Disorders
The video spotlights neurotechnology as a burgeoning alternative to pharmaceuticals for brain‑disorder treatment, emphasizing its capacity to directly modulate neural activity without crossing the blood‑brain barrier. Speakers highlight that synchronized light and sound—so‑called sensory ramps—can activate brain circuits, while brain‑computer interfaces,...
Pulsed Field Ablation Shows Early Promise for VT Treatment
The video discusses the first prospective trial of pulsed‑field ablation (PFA) applied to ventricular tachycardia (VT), a technique previously limited to atrial procedures. Published in Circulation: Arrhythmia and Electrophysiology, the study marks a milestone in expanding PFA to the ventricle. Results...
Why Integrated Technology Matters in Outpatient Surgery
The video spotlights why integrated technology is essential for outpatient surgery, drawing on the speaker’s experience as a physician, investor, and policy‑tech analyst. He observes a fragmented landscape where rising costs and misaligned incentives between volume and value hinder patient...